We studied dosage optimization for metaraminol when managing hypotension during subarachnoid anaesthesia. Twenty patients aged 53 to 84 years, were recruited. Non-invasive blood pressure (BP) and heart rate were recorded one-minutely. A series of four IV metaraminol boluses (0.25 to 1.0 mg per 50 kg adult) were administered. From individual patient time plots of BP, predicted dosages for a 25% elevation in BP were estimated. Dose-related elevations in systolic BP [mean (SD)] occurred following dosages of 0.5 mg [25 (11)%] and 1.0 mg [50 (23)%]. Similar elevations occurred in mean and diastolic BP. Overall estimated dosage (median) to produce a 25% elevation in systolic BP was 0.5 mg (per 50 kg adult). However, individual patient responses varied (10-90th centiles= 0.23 to 0.80 mg). Thus, we now recommend a starting dose of 0.25 mg, increasing to 0.5 mg if necessary, to treat hypotension (25% decrease in systolic BP) during subarachnoid anaesthesia.
Subarachnoid anaesthesia (SA) is a popular method of anaesthesia for surgery involving the lower body. However, SA results in paralysis of the sympathetic vasoconstrictor nerves to the arterioles and venous capacitance vessels, resulting in a fall in peripheral resistance and venous return to the heart 1, 2 . This may result in significant hypotension with more than a 20 to 30% decrease in blood pressure (BP) from baseline. Hypotension can result in ischaemia of vital organs such as the heart 2 , so corrective treatment is desirable. The widely accepted standard treatment for hypotension during SA has until recently consisted of intravenous (IV) fluids and incremental injections of IV ephedrine 1, 3, 4 . However, doubt has been cast recently on the efficacy of such treatments, particularly in the elderly patient where fluid overload and urinary retention may occur and ephedrine can often be ineffective 1, 3, 5 . Smaller volumes of fluid 3, 6, 7 and more potent peripheral vasocon-strictors such as metaraminol, methoxamine and phenylephrine are now being recommended [7] [8] [9] [10] [11] . However, much of this work was performed in obstetric patients using phenylephrine 10, 11 .
Metaraminol is the peripheral vasoconstrictor most commonly used in South East Asia and much of Australasia. Clinical data on its potency and how much one should administer for a given effect is lacking in the literature. In a review of vasopressors, Morgan recommended giving doses of 0.5 to 5.0 mg IV 12 . However, these doses exceed those of our previous studies using infusions of metaraminol, at the time of which we recommended using bolus doses of 0.5 to 1.0 mg 13 . The aim of the present study was to find the optimum dose of metaraminol in adult Chinese patients receiving SA.
PATIENTS AND METHODS
Local ethics committee approval and written informed consent from each patient were obtained. Twenty ASA 1 or 2 patients, all over the age of 50 years, requiring SA for lower body surgery were recruited.
Patients were unpremedicated and fasted overnight. On arrival in the operating theatre intravenous access was established and a fluid load of normal saline 500 ml started, half given before and half given immediately following commencement of SA.
Cardiovascular monitoring consisted of non-invasive blood pressure (BP) measurement taken at one minute intervals, lead II electrocardiogram and pulse oximetry, all performed by the anaesthetic machine (Narkomed 4, North American Drager, Telford, PA, U.S.A.) and monitor (Vitalert 2000, North American Drager). Baseline recordings were made and then the patient turned lateral for SA. Using an aseptic technique, subarachnoid puncture was performed in the lower lumbar spine and 0.5% bupivacaine 2.5 to 3.0 ml (Marcain Spinal 0.5% Heavy, Astra) injected over five seconds. Once the procedure was completed, the patient was returned to a supine-horizontal position and surgery allowed to commence. The study and data collection were performed during the surgery. The sensory height of the block was assessed after 20 minutes using pinprick.
Haemodynamic data were transferred from the anaesthetic machine and monitor to a laptop computer (MacIntosh Powerbook 520C) where it was stored as a text file (ASCII) and graphically displayed using the software program Monitor, version 1.0, developed in our department 14 . After 20 minutes, once the haemodynamic effects of SA had stabilized, a series of four doses of metaraminol were given IV (0.005, 0.005, 0.02 and 0.01 mg kg -1 ), each followed immediately by a 5 ml normal saline flush. For convenience of presentation, these doses will be subsequently standardized to a typical 50 kg Chinese patient for the rest of this paper (i.e. 0.25, 0.25, 1.0 and 0.5 mg (per 50 kg adult)). Following each bolus, 10 to 20 minutes was allowed for the BP to return to the pre-bolus value or plateau, which we assessed from the graphical display of intra-operative haemodynamic data. Blood loss was closely monitored during the procedure and replaced with normal saline as appropriate. If the blood loss exceeded 500 ml, data collection was stopped.
Data Analysis and Statistics
Haemodynamic data were exported into Excel (Microsoft Excel 97, Microsoft Corporation, Redmond, U.S.A.) and systolic, mean and diastolic BP and heart rate were displayed graphically against time for each patient (Figure 1 ). Following each administration of metaraminol lines of "best fit" were plotted on each BP trace (systolic, mean and diastolic). Vertical lines were also plotted that coincided with the initial decrease in heart rate ( Figure 2 ). Estimated values of BP were then calculated from the graph for the period just before (three minutes) each metaraminol administration and for the estimated peak BP response. The latter were estimated from the point where the line of "best fit" crossed the vertical line corresponding to the initial heart rate decrease ( Figure 2 ). The rate of decay of the BP increase (i.e. slope of the line of "best fit") was measured following the 1.0 mg (per 50 kg) dosage. Heart rate was also measured just prior to and at the point of maximum decrease following each metaraminol administration ( Figure 2 ). The reasoning behind our method of analysis is explained in the Discussion.
In each patient, percentage increases for systolic, mean and diastolic BP were calculated from the estimated BP values before and at the "extrapolated peak" after each metaraminol administration. Doseresponse graphs for each patient were then plotted using the percentage increases in BP. Lines of best fit were than calculated using linear regression and the dosage required to give a 25% increase in BP in each patient measured ( Figure 3 ). The coefficients of regression for these lines were compared.
Results are presented as mean (SD or range) unless otherwise stated. Paired Student's t-test was used to make statistical comparisons. P<0.05 was considered statistically significant.
RESULTS
Haemodynamic data from 17 male and three female ASA 1 or 2 (11:9) patients, aged 72 (53 to 84) years, weight 56 (40 to 65) kg are presented. Operations included transurethral resections (16) , inguinal hernia repairs (3) and plating of fractured bones (1) . Three patients had mild chronic obstructive airways disease and were treated with bronchodilators, three patients were non-insulin dependent diabetics and controlled by diet and oral hypoglycaemic drugs and three patients were known hypertensives on a thiazide diuretic (1) or nifedipine (2) . The median level of sensory block after 20 minutes was the 5th (2 to 9) thoracic dermatome.
Numerical differences and percentage changes in BP and heart rate following the four incremental doses of metaraminol are shown in Table 1 . Significant differences in BP existed between the 0.25, 0.5 and 1.0 mg (per 50 kg) doses in nearly all cases (P<0.05). (In some cases the difference between the first 0.25 mg and 0.5 mg doses did not reach significance). The two consecutive 0.25 mg doses were similar in their effects on BP ( Table 1 ). The first 0.25 mg dose caused a greater decrease in heart rate 12 (13) bpm than the second 0.25 mg dose 6 (4) bpm, though this difference did not reach significance (P=0.08). The rates at which BP decreased following the 1.0 mg dose were 3.6 (1.8), 3.1 (1.1) and 2.7 (0.9) mmHg.min -1 for systolic, mean and diastolic BP respectively ( Table 1) .
The estimated mean dose of metaraminol required to produce a 25% increase in systolic, mean and diastolic BP was 0.64 (0.49), 0.49 (0.29) and 0.53 (0.22) mg respectively ( Table 2 ). Median (with percentiles) doses were also calculated ( Table 2) . Mean regression coefficients of the dose-response lines were r = 0.94 (0.05), 0.89 (0.10) and 0.91 (0.07) TABLE 1 Mean (SD) rates of blood pressure decrease ("gradients") after the 1 mg per 50 kg dose. Percentage and absolute increases in systolic, mean and diastolic blood pressures and percentage and absolute decreases in heart rate following the four different dosages of metaraminol.
(1)=first dose and (2) respectively ( Table 2) . Systolic data was fitted better than mean data (P=0.05). Diastolic data could not be fitted in seven of the twenty cases because of the scatter and limited number of data points.
DISCUSSION
Relatively little data, other than our previous work, has been published regarding dosage requirements of metaraminol during SA. Data from the present study showed that in patients over 53 years of age a dose of 0.01 mg.kg -1 of metaraminol (0.5 mg for a 50 kg Chinese adult) was required to raise the BP by 25% during SA. However, we found significant variability between individual patients in the potency of metaraminol, with effective doses for a 50 kg adult ranging from 0.2 to 0.9 mg in 80% of patients ( Table  2) . A 25% increase in BP was chosen as our benchmark because 25% is the accepted threshold for treating hypotension during SA [1] [2] [3] [4] 9, 15 .
Metaraminol was studied because it is the alpha agonist and vasoconstrictor commonly used in Hong Kong and much of Australia and New Zealand, and because it was the agent we had used in much of our previous work 1, 7, 8 . Patients with high levels of sensory blockade (T9-T2) were studied because hypotension was expected to follow SA in these patients. During the study we wished to minimize any alterations in circulating volume. Normal saline 500 ml was used as a fluid load because previously we had shown that similar volumes of colloid (8 ml.kg -1 ) successfully compensated for the venodilation that followed SA 16 . However, crystalloid was preferred in the present study because of the inherent risk of anaphylaxis when using colloids. Patients of ASA 2 classification were included in the study because their illness and medications were considered minor in nature and thus would not affect the overall results of the study. However, in previous studies we had found that emergency cases, such as patients with traumatic hip fractures, were more susceptible to hypotension during SA 16 and these patients were excluded from the study. We also avoided studying any patients where excessive blood loss was likely and when loss exceeded 500 ml, we excluded the resulting data from the study.
Few investigators have previously utilized computerized anaesthetic data collection systems to study regional anaesthesia 14 . This study demonstrated its utility during SA. The ability to visualize real-time haemodynamic data graphically enabled us to determine when the BP increases following metaraminol had returned to baseline or plateau levels and thus when to give the next dose.
Our dosage regimen for metaraminol was based on practice commonly used to measure drug effects in vivo. First, two small 0.25 mg (per 50 kg) doses were given to test for repeatability in response and any cumulative effects. In the present study we found that metaraminol resulted in a reproducible and noncumulative BP elevation (Table 1) , but the heart rate response to the first 0.25 mg dose was exaggerated. Most likely this discrepancy reflected the need in several cases to give the first dose of metaraminol early because of the hypotension, at a time when the initial SA induced decrease in heart rate was still evolving (Figure 1) . Giving a smaller dose first also gave us an indication as to whether the response to the full dose (1 mg) would be excessive, i.e. systolic BP above 200 mmHg. Following the two 0.25 mg doses, a full dose (1 mg) followed by a half dose (0.5 mg) were given, which enabled us to construct dose-response plots for each patient (Figure 3 ). As the number of data points used were small, i.e. four, we assumed a linear rather than sigmoid relationship. However, the use of only four data points did make it impossible to fit data in all cases, particularly when assessing diastolic data. Our choice of a 1 mg (per 50 kg) full dose was based on previous work in which we had recommended using 0.5 to 1.0 mg of metaraminol, this being the dose that gave a satisfactory return to baseline BP during SA 13 . Final results were expressed as percentage changes rather than the numerical difference because percentage changes were more easily related to previously published data and compensation could be made for variations in pre-dose BP between doses and individuals.
Our method of estimating the peak blood pressure increases was novel. We assumed that the onset of vasoconstriction following the injection of metaraminol was almost instantaneous, metaraminol being a direct-acting agonist drug. This assumption was supported by our BP recordings (Figure 1) . Inspection of the BP traces following metaraminol also showed a near linear or zero order, decrease in BP. Thus by plotting lines of "best fit" to the BP traces following metaraminol injection we were able to estimate the peak value of the BP increase ( Figure 2 ). To ensure a rapid onset of effect we flushed each bolus of metaraminol using saline. The use of non-invasive BP measurements at 1-minute intervals enabled us to detect the immediate effects of the metaraminol bolus doses. Individual non-invasive BP measurements have an accuracy of 5-10% 17 , making the use of single maximum BP readings too inaccurate. However, by averaging the data over consecutive readings, we increased this accuracy. The use of direct arterial pressure measurements was considered, but was thought to be not ethically justifiable. Based on the sudden decrease in heart rate following the metaraminol injection, we were able to more accurately pin-point the exact time at which the metaraminol injection took effect. Previous animal work had shown increases in blood pressure to be directly related to decreases in heart rate induced via the baroreceptor reflexes 18 .
The ideal drug profile for correcting hypotension during SA has not yet been defined. Metaraminol's BP profile (Figure 1) shows it to be a drug of rapid onset and short duration, making it perhaps more suitable for use as an IV infusion rather than by incremental injections. Data from our study may be of use in predicting suitable infusion rates. Whether it has the ideal profile for intravenous bolus use in situations where a more prolonged and substantial effect of slower onset is required is questionable. Thus, we plan future work to look at the BP profiles of the other currently available vasopressor agents.
When using the Vitalert 2000 monitor which uses an oscillotonometric method to measure BP, we found that the systolic measurements were more reliable than mean measurements and that diastolic measurements were not suitable for analysis in 35% of cases. Thus, data from the present study endorses our previous use of systolic rather than mean BP when studying the haemodynamic effects of SA 5, 7, 8, 16 .
Heart rate was seen to decrease markedly following each metaraminol injection, a well documented phenomenon. The decrease in heart rate was proportional to the dosage of metaraminol (Table 1 ) when using the 0.5 and 1.0 mg (per 50 kg) doses of metaraminol. The decrease in heart rate was substantial ( Figure 2 ) and often severe with bradycardias of less than 40 bpm in several patients. However, these bradycardias were short-lived and no patient required additional treatment. The decreases in heart rate also mirrored the increases in BP following metaraminol, indicating a direct relationship which was most likely to be baroreceptor mediated (Figure 1) .
The results of our study show that a dose of 0.01 mg kg -1 (i.e. 0.5 mg for a 50 kg adult) will correct hypotension (i.e. a 25% blood pressure decrease) during SA. However, wide variations in vasconstrictor response exist between individuals, and in our study 80% of patients required between half to double this dose. Thus, caution needs to exhibited when first treating hypotension with metaraminol, as excessive hypertension may occur. However, the BP will fall by 3 to 4 mmHg min -1 or 10 mmHg every two to four minutes, so any inadvertent hypertension will be short lived. We now recommend using a lower starting dose of 0.25 mg followed by doses of up to 0.5 mg if necessary.
